[go: up one dir, main page]

WO2004023973A3 - Molecules utilisees a des fins diagnostiques et therapeutiques - Google Patents

Molecules utilisees a des fins diagnostiques et therapeutiques Download PDF

Info

Publication number
WO2004023973A3
WO2004023973A3 PCT/US2003/028227 US0328227W WO2004023973A3 WO 2004023973 A3 WO2004023973 A3 WO 2004023973A3 US 0328227 W US0328227 W US 0328227W WO 2004023973 A3 WO2004023973 A3 WO 2004023973A3
Authority
WO
WIPO (PCT)
Prior art keywords
dithp
provides
therapeutics
diagnostics
diagnostic assays
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/028227
Other languages
English (en)
Other versions
WO2004023973A2 (fr
Inventor
Jeanette P Schmidt
Rachel J Wright
Christopher M Bruns
Mirjana M Marjanovic
Fan Shen
Toinette A Harthshorne
Martin T Suchorolski
Christina M Altus
Steven J Pitts
Linda V Elder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Priority to AU2003289716A priority Critical patent/AU2003289716A1/en
Publication of WO2004023973A2 publication Critical patent/WO2004023973A2/fr
Publication of WO2004023973A3 publication Critical patent/WO2004023973A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des polynucléotides humains purifiés utilisés à des fins diagnostiques et thérapeutiques (dithp) ainsi que des polypeptides (DITHP) codés par ces dithp. L'invention concerne également l'utilisation de ces dithp, ou de leurs compléments, oligonucléotides ou fragments dans des analyses diagnostiques. L'invention concerne des vecteurs et des cellules hôtes contenant ces dithp et permettant l'expression de DITHP. L'invention concerne également l'utilisation de DITHP isolés et purifiés pour induire des anticorps et passer au crible des banques de composés ainsi que l'utilisation d'anticorps anti-DITHP dans des analyses diagnostiques. L'invention concerne également des microéchantillons contenant ces dithp et leurs procédés d'utilisation.
PCT/US2003/028227 2002-09-12 2003-09-12 Molecules utilisees a des fins diagnostiques et therapeutiques Ceased WO2004023973A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003289716A AU2003289716A1 (en) 2002-09-12 2003-09-12 Molecules for diagnostics and therapeutics

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41026002P 2002-09-12 2002-09-12
US41025902P 2002-09-12 2002-09-12
US60/410,260 2002-09-12
US60/410,259 2002-09-12

Publications (2)

Publication Number Publication Date
WO2004023973A2 WO2004023973A2 (fr) 2004-03-25
WO2004023973A3 true WO2004023973A3 (fr) 2004-09-23

Family

ID=31997928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/028227 Ceased WO2004023973A2 (fr) 2002-09-12 2003-09-12 Molecules utilisees a des fins diagnostiques et therapeutiques

Country Status (2)

Country Link
AU (1) AU2003289716A1 (fr)
WO (1) WO2004023973A2 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718774B2 (en) 2006-11-08 2010-05-18 Macrogenics, Inc. TES7 and antibodies that bind thereto
US8168180B2 (en) 2002-11-27 2012-05-01 Technion Research & Development Foundation Ltd. Methods and compositions for modulating angiogenesis
US8461303B2 (en) 2007-08-02 2013-06-11 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
US8470992B2 (en) 2005-12-20 2013-06-25 Sbi Biotech Co., Ltd. Anti-ILT7 antibody
US8927700B2 (en) 2009-08-21 2015-01-06 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US9127268B2 (en) 2009-12-11 2015-09-08 Atyr Pharma, Inc. Aminoacyl tRNA synthetases for modulating inflammation
US9273302B2 (en) 2012-02-16 2016-03-01 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US9284609B2 (en) 2005-09-12 2016-03-15 The Brigham And Women's Hospital, Inc. Recurrent gene fusions in prostate cancer
US9303291B2 (en) 2007-07-06 2016-04-05 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
US9340780B2 (en) 2010-05-03 2016-05-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases
US9422539B2 (en) 2010-07-12 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
US9428743B2 (en) 2010-08-25 2016-08-30 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
US11505590B2 (en) 2016-04-08 2022-11-22 Immunocore Limited T cell receptors
US11624066B2 (en) 2018-02-26 2023-04-11 Teesside University Neurodegenerative disorders
US12065475B2 (en) 2022-08-18 2024-08-20 Immunocore Ltd T cell receptors and fusion proteins thereof

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2462670A1 (fr) * 2001-10-22 2003-07-03 Children's Medical Center Corporation Canal cations catsper2 specifique du sperme et utilisations correspondantes
WO2004016733A2 (fr) 2002-08-16 2004-02-26 Agensys, Inc. Acides nucleiques et proteines correspondantes connues sous 251p5g2 que l'on utilise dans le traitement et la detection de cancers
WO2004053079A2 (fr) 2002-12-06 2004-06-24 Diadexus, Inc. Compositions, variants d'epissage et methodes concernant des genes et des proteines specifiques des ovaires
US8871709B2 (en) * 2003-02-05 2014-10-28 Queensland University of Technolgy Synthetic chimeric proteins comprising epidermal growth factor and vitronectin
US7344860B2 (en) 2003-04-03 2008-03-18 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
WO2004094623A2 (fr) * 2003-04-04 2004-11-04 Incyte Corporation Proteines d'adhesion cellulaire et de matrice extracellulaire
WO2004101616A1 (fr) * 2003-05-14 2004-11-25 Sumitomo Chemical Company, Limited Proteine mutante d'epissage du recepteur x $g(a) du foie, gene correspondant et leur utilisation
US7341850B2 (en) 2003-08-18 2008-03-11 Wyeth Human LXRα variants
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
AU2004289335A1 (en) * 2003-11-12 2005-05-26 Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
JP4936899B2 (ja) * 2003-12-24 2012-05-23 ジー２ インフラメイション ピーティーワイ エルティーディー ヒトまたはヒト化Ｃ５ａＲをコードするポリヌクレオチドを含むトランスジェニック非ヒト哺乳動物
WO2005076012A2 (fr) * 2004-01-30 2005-08-18 Five Prime Therapeutics, Inc. Nouveaux variants d'epissure et methodes d'utilisation associees
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
EP1586587A1 (fr) * 2004-04-16 2005-10-19 Exonhit Therapeutics SA Préparations et méthodes pour détecter l'angiogenèse
PT1755661E (pt) 2004-05-12 2014-06-03 Brigham & Womens Hospital A utilização de gelsolina para o tratamento de infeções
EP1794314A2 (fr) * 2004-07-23 2007-06-13 Bayer HealthCare AG Agents diagnostiques et therapeutiques pour pathologies associees au recepteur 1 de peptide intestinal vasoactif (vpac1)
WO2006008008A2 (fr) * 2004-07-23 2006-01-26 Bayer Healthcare Ag Agents diagnostiques et therapeutiques pour pathologies associees au facteur nucleaire d'hepatocyte 4, alpha (hnf4a)
AU2005299089B2 (en) * 2004-10-21 2011-08-18 Eberhard Karls Universitaet Tuebingen KASPP (LRKK2) gene, its production and use for the detection and treatment of neurodegenerative disorders
CA2590751A1 (fr) 2004-12-13 2006-06-22 Roy Rabindranauth Sooknanan Sequences polynucleotidiques et polypeptidiques participant au remodelage osseux
KR100664587B1 (ko) * 2004-12-22 2007-01-04 김현기 인간 암 억제 유전자, 이에 의해 코딩되는 단백질, 이를포함하는 발현 벡터 및 이 벡터로 형질전환된 세포
US20090133135A1 (en) 2005-06-01 2009-05-21 Evotec Neurosciences Gmbh Diagnostic and Therapeutic Target SLC39A11 Proteins for Neurodegenerative Diseases
EP1739092A1 (fr) * 2005-06-28 2007-01-03 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Antagonistes peptidiques des complexes sémaphorine/neuropiline de classe III
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
AU2014265023A1 (en) * 2005-12-20 2014-12-04 Sbi Biotech Co, Ltd. Anti-ILT7 Antibody
AU2012244391B2 (en) * 2005-12-20 2014-09-11 Sbi Biotech Co., Ltd. Anti-ILT7 antibody
US8383799B2 (en) 2006-01-20 2013-02-26 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
ES2539830T3 (es) * 2006-01-20 2015-07-06 Cell Signaling Technology, Inc. ROS quinasa mutante y de translocación en el carcinoma pulmonar no microcítico humano
US20070192885A1 (en) * 2006-01-26 2007-08-16 Daniel Chelsky TAT-039 and methods of assessing and treating cancer
WO2007089783A2 (fr) * 2006-01-30 2007-08-09 Caprion Pharmaceuticals, Inc. Tat-044 et méthodes d'évaluation et de traitement du cancer
US20070269434A1 (en) * 2006-01-31 2007-11-22 Daniel Chelsky TAT-041 and methods of assessing and treating cancer
CN107085113B (zh) 2006-03-15 2020-07-17 布赖汉姆妇女医院有限公司 凝溶胶蛋白诊断和治疗炎性疾病的用途
WO2007106577A2 (fr) 2006-03-15 2007-09-20 The Brigham And Women's Hospital, Inc. Utilisation de la gelsoline pour traiter la sclérose en plaques et pour diagnostiquer des maladies neurologiques
US7452985B2 (en) 2006-08-17 2008-11-18 Visgeneer, Inc. Human Ron-related gene variant associated with cancers
EP1892248A1 (fr) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Protéines liantes spécifiques et de haute affinité comprenant des domaines SH3 de FYN kinase modifiés
US9689879B2 (en) 2006-08-21 2017-06-27 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
US9513296B2 (en) 2006-08-21 2016-12-06 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
US8119772B2 (en) * 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
WO2009020521A2 (fr) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification et traitement de tumeurs de la prostate répondant aux œstrogènes
US7892760B2 (en) 2007-11-19 2011-02-22 Celera Corporation Lung cancer markers, and uses thereof
JP2011509652A (ja) * 2008-01-07 2011-03-31 パトリス・リミテッド Ｔａｔａ結合蛋白会合因子１５を含むｂａｒｂ４標的、ｂａｒｂ４と呼ばれる抗体、ｂａｒｂ４関連抗体、ならびにそれらを作製および使用する方法
ES2634263T3 (es) 2008-01-25 2017-09-27 The General Hospital Corporation Usos de diagnóstico terapéuticos de gelsolina en insuficiencia renal
US8557575B2 (en) 2008-01-28 2013-10-15 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies
AU2013202400B2 (en) * 2008-07-16 2014-10-09 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
ES2613841T3 (es) 2008-07-16 2017-05-26 Medical And Biological Laboratories Co., Ltd. Anticuerpo anti-CLCP1 humano y uso del mismo
EP2328911A4 (fr) * 2008-09-22 2012-03-14 Cedars Sinai Medical Center Md-2 humaine sous sa forme courte utilisée comme régulateur négatif de la signalisation par le récepteur de type toll-4
US9512196B2 (en) 2008-09-22 2016-12-06 Cedars-Sinai Medical Center Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
ES2573954T3 (es) * 2008-12-30 2016-06-13 Children's Medical Center Corporation Método de predicción de apendicitis aguda
ES2742251T3 (es) 2009-03-16 2020-02-13 Pangu Biopharma Ltd Composiciones y procedimientos que comprenden variantes de splicing de histidil-tarn sintetasa que tienen actividades biológicas no canónicas
JP4495776B1 (ja) * 2009-07-30 2010-07-07 日本製薬株式会社 融合蛋白質
CN102712953A (zh) 2009-09-17 2012-10-03 密歇根大学董事会 前列腺癌中的复发性基因融合物
CN103755809B (zh) 2009-11-30 2016-06-01 霍夫曼-拉罗奇有限公司 治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US8828395B2 (en) 2009-12-11 2014-09-09 Atyr Pharma, Inc. Antibodies that bind tyrosyl-tRNA synthetases
WO2011130434A2 (fr) 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Anticorps qui se lient au cd27 humain et utilisations de ceux-ci
US20130303439A1 (en) * 2010-09-30 2013-11-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Chimeric peptides including a penetrating peptide and a binding domain of pp2a catalytic subunit to caspase-9
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
WO2013022982A2 (fr) 2011-08-09 2013-02-14 Atyr Pharma, Inc. Polypeptides tyrosyl-arnt synthétase pégylés
EP2771689A4 (fr) * 2011-10-26 2015-06-03 Nuclea Biotechnologies Inc Peptides usp2a et anticorps
CA2872467C (fr) 2012-05-01 2019-05-14 Fujifilm Corporation Procede de culture de cellules souches pluripotentes et polypeptide a utiliser dans ledit procede
PL3685855T3 (pl) 2012-10-05 2024-04-08 Kadmon Corporation, Llc Ludzkie przeciwciała anty-vegfr-2/kdr
UY35457A (es) 2013-03-14 2014-10-31 Bayer Healthcare Llc ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA ß
CN107771285A (zh) 2015-06-08 2018-03-06 阿奎尔诊断有限公司 方法
US11391744B2 (en) 2015-06-08 2022-07-19 Arquer Diagnostic Limited Methods and kits
US11390656B2 (en) * 2015-08-04 2022-07-19 New York University Progranulin (PGRN) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
IL321334A (en) 2016-03-10 2025-08-01 Viela Bio Inc ILT7 binding molecules and methods of using them
US20240002459A1 (en) * 2016-07-14 2024-01-04 Emory University Granulin Compositions and Uses Related Thereto
ES2994451T3 (en) 2017-04-20 2025-01-24 Atyr Pharma Inc Compositions for treating lung inflammation
SG11201910101SA (en) 2017-05-08 2019-11-28 Gritstone Oncology Inc Alphavirus neoantigen vectors
JP7348844B2 (ja) 2017-06-07 2023-09-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 内部移行酵素のための組成物および方法
ES2985828T3 (es) * 2017-07-31 2024-11-07 Reflection Biotechnologies Ltd Modelos celulares y terapias para enfermedades oculares
CN118955720A (zh) 2018-01-04 2024-11-15 伊科尼克治疗公司 抗组织因子抗体、抗体-药物缀合物及相关方法
AU2019218892B2 (en) 2018-02-07 2025-08-14 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
US20210198374A1 (en) 2018-04-17 2021-07-01 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
MA52626A (fr) 2018-05-17 2021-03-24 Regeneron Pharma Anticorps anti-cd63, conjugués et leurs utilisations
BR112021024127A2 (pt) 2019-05-30 2022-04-26 Gritstone Bio Inc Adenovírus modificado
CN111859913B (zh) * 2020-06-12 2024-04-12 北京百度网讯科技有限公司 风控特征因子的处理方法、装置、电子设备及存储介质
WO2022032196A2 (fr) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Cassettes de vaccin à plusieurs épitopes
JP2024516783A (ja) * 2021-03-30 2024-04-17 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム がんのバイオマーカーおよび治療標的としてのシトルリン化タンパク質
WO2024163607A2 (fr) * 2023-02-02 2024-08-08 Board Of Regents, The University Of Texas System Récepteurs de lymphocytes t ciblant l'egfr et leurs procédés d'utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053531A2 (fr) * 2000-01-18 2001-07-26 Pharmacia Corporation Acides nucleiques, polypeptides, vecteurs et cellules provenant d'un tissu d'osteoarthrite

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053531A2 (fr) * 2000-01-18 2001-07-26 Pharmacia Corporation Acides nucleiques, polypeptides, vecteurs et cellules provenant d'un tissu d'osteoarthrite

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168180B2 (en) 2002-11-27 2012-05-01 Technion Research & Development Foundation Ltd. Methods and compositions for modulating angiogenesis
US9284609B2 (en) 2005-09-12 2016-03-15 The Brigham And Women's Hospital, Inc. Recurrent gene fusions in prostate cancer
CN105111311B (zh) * 2005-12-20 2019-10-18 Sbi生物技术有限公司 抗ilt7抗体
US8470992B2 (en) 2005-12-20 2013-06-25 Sbi Biotech Co., Ltd. Anti-ILT7 antibody
CN105111311A (zh) * 2005-12-20 2015-12-02 Sbi生物技术有限公司 抗ilt7抗体
US8216570B2 (en) 2006-11-08 2012-07-10 Macrogenics, Inc. TES7 and antibodies that bind thereto
US7718774B2 (en) 2006-11-08 2010-05-18 Macrogenics, Inc. TES7 and antibodies that bind thereto
US9303291B2 (en) 2007-07-06 2016-04-05 The Regents Of The University Of Michigan MIPOL1-ETV1 gene rearrangements
US8461303B2 (en) 2007-08-02 2013-06-11 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
US9176139B2 (en) 2007-08-02 2015-11-03 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
US8679485B2 (en) 2007-08-02 2014-03-25 Gilead Biologics, Inc. Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US9289447B2 (en) 2009-01-06 2016-03-22 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US8927700B2 (en) 2009-08-21 2015-01-06 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
US9328340B2 (en) 2009-12-11 2016-05-03 Atyr Pharma, Inc. Amino acyl tRNA synthetases for modulating inflammation
US9540628B2 (en) 2009-12-11 2017-01-10 Atyr Pharma, Inc. Aminoacyl tRNA synthetases for modulating inflammation
US9127268B2 (en) 2009-12-11 2015-09-08 Atyr Pharma, Inc. Aminoacyl tRNA synthetases for modulating inflammation
US9340780B2 (en) 2010-05-03 2016-05-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases
US9422539B2 (en) 2010-07-12 2016-08-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-tRNA synthetases
US9428743B2 (en) 2010-08-25 2016-08-30 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
US9273302B2 (en) 2012-02-16 2016-03-01 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
US11505590B2 (en) 2016-04-08 2022-11-22 Immunocore Limited T cell receptors
US11624066B2 (en) 2018-02-26 2023-04-11 Teesside University Neurodegenerative disorders
US12065475B2 (en) 2022-08-18 2024-08-20 Immunocore Ltd T cell receptors and fusion proteins thereof

Also Published As

Publication number Publication date
AU2003289716A8 (en) 2004-04-30
AU2003289716A1 (en) 2004-04-30
WO2004023973A2 (fr) 2004-03-25

Similar Documents

Publication Publication Date Title
WO2004023973A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2002097031A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2000073509A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2002083876A3 (fr) Molecules secretoires
WO2004037999A3 (fr) Adn et proteines 3 de type a34 et a33, anticorps associes et methodes de traitement associees
WO2005056600A3 (fr) Anticorps monoclonaux se liant ou neutralisant le virus de la dengue
WO2006056480A3 (fr) Moyens et procedes pour la detection d'adn methyle
WO2008073914A3 (fr) Expression et criblage à haut débit de bibliothèques d'adn exprimé complexes dans les champignons filamenteux
WO2007054520A3 (fr) Procedes d'identification du microarn et leurs applications en termes de recherche et de sante humaine
WO2002046228A3 (fr) Recepteur de la toxine du b. anthracis
WO2003062376A3 (fr) Molécules pour le diagnostic et la thérapeutique
WO2002040715A3 (fr) Molecules permettant la detection et le traitement de maladies
WO2002020756A3 (fr) Molécules sécrétoires
WO2001062927A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2008124170A3 (fr) Choix d'anticorps spécifiques du tnfα humain
WO2003062385A3 (fr) Molecules secretoires
WO2004100886A3 (fr) Polynucleotides et polypeptides associes a la voie nf-kb
WO2001062922A3 (fr) Molecules destinees a la detection et au traitement de maladies
WO2002020754A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2005069854A3 (fr) Procedes et materiaux ayant trait a de nouveaux polypeptides et polynucleotides contenant le domaine c1q
WO2002055738A3 (fr) Molecules pour la detection et le traitement de maladies
WO2001062918A3 (fr) Molecules secretoires
WO2002079473A3 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2003083078A3 (fr) Nouvelle proteine de surface cellulaire avec replis d'hemoglobine, bgs-19
WO2001021836A3 (fr) Molecules pour le diagnostic et la therapeutique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP